Use of infliximab‐daclizumab combination for the treatment of acute and chronic graft‐versus‐host disease of the liver and gut

Infliximab‐daclizumab was used to treat acute and chronic liver and gut graft‐versus‐host disease (GVHD) in two children after standard immunosuppressive therapy failed. Infliximab (10 mg/kg weekly, 4 doses) and daclizumab (1 mg/kg, days 1, 4, 8, 15, and 22) were given over 1 month. In case 1, grade 2 chronic GVHD of the liver developed 1 year after transplantation and failed to improve with tacrolimus, mycophenolate mofetil, and prednisone. In case 2, corticosteroid‐unresponsive grade 3 acute liver and gut GVHD developed on day +37. In both patients, GVHD responded to the infliximab‐daclizumab regimen without toxicity and immunosuppressive therapy was discontinued. Pediatr Blood Cancer 2007;49:212–215. © 2005 Wiley‐Liss, Inc.